Merck KGaA looks at job cuts; Heptares lands $103M pact with Takeda;

 @FierceBiotech: Beleaguered Ambrilia faces bankruptcy. Report | Follow @FierceBiotech  

 @JohnCFierce: CF Foundation clearly very impressed with Vertex. Doubles down on R&D pact, adds $75M. Story | Follow @JohnCFierce

> Slammed by a series of setbacks in the clinic, the Financial Times Deutschland reports that Merck KGaA is looking at potential job cuts at Merck Serono. The axe may fall particularly hard at its headquarters. Article

> Heptares Therapeutics and Takeda Pharmaceutical inked a two-year drug discovery collaboration focused on a single G-protein coupled receptor that plays a role in the pathology of central nervous system disorders. Heptares gets $2.7 million up front, a $4.5 million equity stake and up to $96 million in milestones. Item

> Novelos Therapeutics has acquired Cellectar, a Wisconsin-based drug development company, in a stock-for-stock transaction. Novelos release

> Alnylam Pharmaceuticals is extending its collaboration with AlCana Technologies and the University of British Columbia. Story

Pharma News

@FiercePharma: GSK readies 500 reps for Horizant launch. Story | Follow @FiercePharma

> J&J agrees to pay $70M in corruption probe. News

> Merck teams with Sun Pharma on branded generics. Item

> Amgen beefs up in Brazil with $215M deal. Article

Biotech IT News

> LifeMap born to create stem cell database. Item 

> DZS Software enters partnership with Medidata. Story 

> PatientsLikeMe reveals strategy change. Article 

> Informatics enables new "point-of-care" trials. Report 

> Complete Genomics stocks up public genome repository. Item 

Medical Device News

> Depuy pays $7.9 million to end UK bribe case. Story 

> Medtronic combines U.S. cardiac, vascular sales groups. Report 

> PixelOptics snags $45M investment. Item 

> Biotronik responds to NYT report. Article 

> Study: Patients in stroke device trials don't resemble typical patients. Report 

> Endo to buy AMS for $2.9M. News 

> St. Jude signs contract with GPO Novation. Item 

And Finally... Investigators at Rockefeller University say that bullying has an impact on brain chemistry. Release

Suggested Articles

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.